Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
District of Columbia: below-average open trial sites
727 of 2,316 in-state trials are recruiting (31%); below the 37% national average by 6 percentage points.
According to ClinicalTrials.gov-derived indexes, District of Columbia sits in the upper half of US states by in-state trial count (#25 of 52 states by registered in-state trial count).
District of Columbia: 2,316 US clinical trials with in-state sites, 727 recruiting.
District of Columbia has 2,316 registered US clinical trials with a study site in-state, 727 of them currently recruiting (below the 37% national average by 6 percentage points). 599 of these trials are in Phase 3 (late-stage) and 560 in Phase 2. The most frequently studied condition in District of Columbia is HIV Infections, with 125 linked trials.
Mid-pack research density
District of Columbia sits in the upper half of the state corpus, so volume is meaningful but not hub-scale. Use condition and sponsor rollups below to see what drives the in-state mix.
Below-average open enrollment
District of Columbia still shows 727 recruiting of 2,316 in-state trials (31% open), but below the 37% national average by 6 percentage points, so archived statuses weigh heavier than the national baseline.
- 31%
- open (below national share)
- 727
- still recruiting despite cool share
- 560
- Phase 2 rows in this footprint
- 125
- top: HIV Infections
Recruiting share is below the 37% national average by 6 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
District of Columbia vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
2,316 Top 48% more indexed trials than 52% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for District of Columbia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
District of Columbia open-enrollment share sits below the national baseline.
727 of 2,316 in-state trials (31.4%) are recruiting, against 37% nationally (-5.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Washington D.C. dominates District of Columbia's trial geography.
Washington D.C. lists 2,307 of 2,316 in-state trials (99.6%) across 742 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
HIV Infections is the most-studied condition in District of Columbia.
125 of 2,316 in-state trials (5.4%) list HIV Infections. That is a local concentration figure, not a national disease ranking.
-
District of Columbia sponsorship is fragmented across many organizations.
National Cancer Institute (NCI) appears on 90 of 2,316 in-state trials (3.9%). Sponsor identity is as filed on ClinicalTrials.gov.
-
1,036 District of Columbia trials carry a completed status.
1,036 of 2,316 (44.7%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 1,036 |
| Recruiting | 727 |
| Active | 553 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 599 |
| Phase 2 | 560 |
| NA | 424 |
| Phase 1 | 295 |
| Phase 4 | 81 |
| Early Phase 1 | 6 |
Top Conditions
Top Sponsors
Where trials run in District of Columbia
Washington D.C. carries 2,307 of District of Columbia's 2,316 indexed trials (100%) across 742 named sites, ahead of Georgetown at 5. 2 cities clear five listed trials, together naming 746 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Washington D.C. | 2,307 | 742 |
| Georgetown | 5 | 4 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Trial size large
District of Columbia's in-state trials target 4,246 patients on average (p69 by trial size among 52 states with enrollment data), larger, multi-site studies than most states.
District of Columbia: in-state trial volume sits mid-pack
Geography is concentrated: Washington D.C. alone accounts for 100% of District of Columbia's indexed trials (2,307 of 2,316), with Georgetown a distant second at 5.
Phase mix: 599 Phase 3 vs 560 Phase 2 (balanced across stages).
Top condition: HIV Infections (125 trials); top sponsor National Cancer Institute (NCI) (90).
mid-volume · mid-open figures (2,316 trials · 31% open) describe registry geography under the trial size large read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near District of Columbia on in-state trial volume
Cross-state peers under the trial size large read (mid-volume · mid-open), not the same-state browse list.
Similar mid-volume peers (± open share)
Similar mid-open peers (± trial volume)
- Vermont · 31% recruiting · 191 trials
- Colorado · 31% recruiting · 5,273 trials
- South Dakota · 31% recruiting · 273 trials
- Georgia · 32% recruiting · 5,195 trials
- Kentucky · 32% recruiting · 2,183 trials